OpenLB
Open Library of Bioscience
Advanced Search
Journal of the National Comprehensive Cancer Network : JNCCN
Mar 28, 2025;23 (3.5):

CLO25-053: Real-World Evidence of Survival in Patients With Metastatic NSCLC Treated With First-Line Immune Checkpoint Inhibitors Beyond Progression.

Natalie Johns, Alexander Rudich, Songzhu Zhao, Kenneth Chian, Po-Lan Su, Adam Khorasanchi, Jinesh Gheeya, Daniel Spakowicz, Lai Wei, Logan Roof, Asrar Alahmadi, Regan Memmott, Jacob Kaufman, Carolyn Presley, Kai He, Peter Shields, Christian Rolfo, David Carbone, Dwight Owen, Mingjia Li
Author Information
  1. Natalie Johns: 1The Ohio State University College of Medicine, Columbus, OH.
  2. Alexander Rudich: 1The Ohio State University College of Medicine, Columbus, OH.
  3. Songzhu Zhao: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  4. Kenneth Chian: 1The Ohio State University College of Medicine, Columbus, OH.
  5. Po-Lan Su: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  6. Adam Khorasanchi: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  7. Jinesh Gheeya: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  8. Daniel Spakowicz: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  9. Lai Wei: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  10. Logan Roof: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  11. Asrar Alahmadi: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  12. Regan Memmott: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  13. Jacob Kaufman: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  14. Carolyn Presley: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  15. Kai He: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  16. Peter Shields: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  17. Christian Rolfo: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  18. David Carbone: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  19. Dwight Owen: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
  20. Mingjia Li: 2The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH.
PMID: 40159135 DOI: 10.6004/jnccn.2024.7160

Abstract

No abstract text available.

Journal Article

Word Cloud

Created with Highcharts 10.0.0CLO25-053:Real-WorldEvidenceSurvivalPatientsMetastaticNSCLCTreatedFirst-LineImmuneCheckpointInhibitorsBeyondProgression

Similar Articles

Cited By

No available data.